Comparing the current results to its competitors, Dariohealth reported Revenue decrease in the 1 quarter 2026 year on year by -11.59 %, despite the revenue increase by the most of its competitors of 16.4 %, recorded in the same quarter.
Dariohealth 's Comment on Competition and Industry Peers
The company originated as a direct-to-consumer (D2C) provider, developing digital behavioral self-care programs and integrated medical devices. It has invested over $500 million in technology and completed more than 100 clinical and real-world evidence studies demonstrating clinical and health outcomes. Its proprietary artificial intelligence (AI) is trained on 13 billion data points collected from connected hardware devices over more than a decade, distinguishing it from competitors that rely on publicly available or self-reported data. This AI-driven personalization supports high user engagement and clinical outcomes across various medical conditions. The company serves both D2C and business-to-business (B2B) markets, using rapid innovation cycles from D2C to enhance B2B offerings, resulting in high user satisfaction, adherence, and return on investment. In the pharmaceutical sector, Novo Nordisk is noted for its FDA approval of the oral Wegovy (semaglutide) in December 2025, which addresses obesity and related side effects by reducing barriers to patient use. Novo Nordisk is identified as a competitor in filings.
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Lifestance Health Group Inc is a mental health care company that provides comprehensive outpatient services. Their business model focuses on delivering personalized, evidence-based treatments to individuals struggling with various mental health conditions. They aim to optimize patient outcomes by employing a collaborative, integrated approach that combines therapy, medication management, and innovative technology solutions.
Odyssey Health Inc is a healthcare organization that employs a subscription-based business model. The company provides comprehensive medical services to its members for a monthly fee, offering personalized healthcare solutions and a range of preventative care services. Through this model, Odyssey Health aims to ensure accessible and affordable healthcare for individuals and families.
P3 Health Partners Inc operates on a value-based care model, aiming to provide comprehensive, coordinated, and proactive healthcare services to patients. They focus on delivering personalized care through an interdisciplinary team including primary care physicians, specialists, care coordinators, and behavioral health professionals. P3 Health Partners Inc also aims to reduce healthcare costs by improving patient outcomes and preventing hospital readmissions through their collaborative and patient-centered approach.
Sources:
Dariohealth Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dariohealth Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
